Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.

about

The association between myocardial infarction and intravitreal bevacizumab injection.

P2860

Q55122457-C8FFE452-41FE-4731-8A01-A57E8A9A0E58

P2860

Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.

Item

http://www.wikidata.org/entity/Q40361420

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Intravitreal Bevacizumab for t ...... ferative Diabetic Retinopathy.

@en

type

Item

label

Intravitreal Bevacizumab for t ...... ferative Diabetic Retinopathy.

@en

prefLabel

Intravitreal Bevacizumab for t ...... ferative Diabetic Retinopathy.

@en

P1476

Intravitreal Bevacizumab for t ...... ferative Diabetic Retinopathy.

@en

P2093

Albert M Maguire

http://www.w3.org/2001/XMLSchema#string

Alexander J Brucker

http://www.w3.org/2001/XMLSchema#string

Anastasia Traband

http://www.w3.org/2001/XMLSchema#string

Anton M Kolomeyer

http://www.w3.org/2001/XMLSchema#string

Benjamin J Kim

http://www.w3.org/2001/XMLSchema#string

Rupin N Parikh

http://www.w3.org/2001/XMLSchema#string

P2860

Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Postoperative complications associated with 25-gauge pars plana vitrectomy.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.

Proper method for calculating average visual acuity.

Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.

Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy.

P304

194-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJO.2017.01.010

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

Brian L VanderBeek

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28130042

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5376507

http://www.w3.org/2001/XMLSchema#string

Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.

about

P2860

P2860

Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932